Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, Inc. ... advancing a new standard of respiratory critical care, will ... August 5, 2014 before the open of the ... will host a live teleconference and webcast at ... conference call, Discovery Labs, management will discuss the ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation (IMCL) ... medicine, treatment of infectious diseases as well as ... and prevention of pathologies like cardiovascular disease, Alzheimer,s ... 2014, ImmunoClin Corporation will complete the strategic relocation ... D.C. , a key center of North ...
(Date:7/29/2014)... 2014 Genera Energy Inc. ... innovation and supply chain advancements, has announced the ... Energy Grange™ and Supply ASSURE™. Both systems ... testing aimed at consolidating and simplifying the entire ... farmers and feedstock end users. , “Through the ...
(Date:7/29/2014)... July 29, 2014  United Therapeutics Corporation (NASDAQ: ... financial results for the second quarter ended ... shows that our medicines are reaching increasing ... hypertension (PAH)," said Martine Rothblatt, Ph.D., United ... commercial launch this quarter of our extended-release ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 24th Annual Roth ... takes place on Tuesday, March 13 at 2:00 p.m. Pacific ... webcast and may be accessed on the Company,s website at ...
... ATLANTA, March 7, 2012 Harriet L. Robinson, Ph.D., ... a biotech company specializing in the development of HIV/AIDS ... scientists may be one step closer to a vaccine ... study results were unveiled by Dr. Robinson during a ...
... BETHESDA, Md., March 7, 2012   Spherix Incorporated ... innovator in biotechnology for therapy in diabetes, metabolic ... regulatory consulting services to food, supplement, biotechnology and ... its drug candidates, SPX-106T, arrested development and reduced ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 2SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 3SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease 4
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Business Intelligence (BI) Market 2014-2018" report to their ... The term BI refers to applications and ... or analyzing information about a company,s operations. BI help ... their business; for example, metrics on sales, production, and ...
(Date:7/29/2014)... of a stroke is an immensely complex challenge ... as effective therapy. Advancing such knowledge to improve ... focus of research by Sergei Adamovich, associate professor ... faculty more than a decade ago. It is ... from sources such as the National Institutes of ...
(Date:7/29/2014)... YORK , July 29, 2014  When it comes to ... new devices, if not the last. However, when it comes to ... Though the market for the Internet of Things and its ... make an impact in the healthcare industry, whether it,s in the ... to keep us fit. With that in mind, InformationWeek ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3
... 2013Dr. Carissa Klein of Australia was awarded the APEC ... by John Wiley & Sons, Inc., and Elsevier, on ... Research and Technology. Dr. Klein,s selection is ... Queensland that uniquely addresses the issue of sustainable ocean ...
... The strain of cholera that has sickened thousands in Haiti ... to the island over the past three years as some ... mBio , the online open-access journal of the American Society ... are consistent with earlier findings that indicate Vibrio cholerae ...
... TEMPE, Ariz -- Knowing virtually everything about how the ... for instance, precisely how particular cells develop into ... in understanding the basics of what drives biological processes. ... advances in medical science, bioengineering and related areas. ...
Cached Biology News:ASPIRE prize winner balances ocean conservation and socioeconomic viability 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3Biomedical research revealing secrets of cell behavior 2
Request Info...
Prepared in distilled water....
... white. The extinction coefficient , E(1%) at ... phosphate-buffered saline, pH 7.4, containing ... 50% glycerol. Avidin (from egg white) is conjugated ... molecular sieving and is completely ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
Biology Products: